All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Retreatment of patients with refractory large B-cell lymphoma with axicabtagene ciloleucel in ZUMA-1
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to Frederick Locke, Moffitt Cancer Center, Tampa, US. In this video, he discusses the retreatment of patients with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in the ZUMA-1 study.
Frederick Locke describes the data from the 14 patients in this pivotal, multicenter, phase I/II study who received retreatment with axi-cel, including medium duration of response and complete response rates. He also discusses the incidence of neurological adverse events which were lower after retreatment.
Retreatment of patients with refractory large B-cell lymphoma with axicabtagene ciloleucel in ZUMA-1
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?